Cannabis and Dopamine: What Animal Brains Show About Reward, Cues, and Withdrawal

In animal models, cannabinoids activate the mesolimbic dopamine system, the same reward circuit engaged by other drugs of abuse. Dopamine release rises with drug exposure and with cues that predict drug availability. During withdrawal, dopamine signaling drops, consistent with negative affect and reduced motivation seen in withdrawal syndromes.

Pharmacologically disrupting endocannabinoid signaling reduces drug-evoked dopamine increases and lowers dopamine responses to reward-predictive cues. This places cannabinoid receptors, especially CB1, as key modulators of how strongly rewards and their signals trigger dopamine release.

The review argues that cannabis is not an exception in dopamine circuitry terms. At the level of mesolimbic signaling in animals, it aligns with other addictive drugs.

The idea that cannabis sits outside the classic addiction framework is common. At the circuit level in animals, this review describes a different story. Cannabinoids engage the same mesolimbic dopamine pathway, show cue-linked dopamine bursts, and exhibit withdrawal-related dips in dopamine, mirroring patterns seen with other drugs of abuse.

Translation to humans is not straightforward. Human neuroimaging of THC shows smaller and less consistent dopamine changes than stimulants, and clinical attempts to blunt reward through CB1 antagonism ran into safety problems, including mood-related adverse effects. The mechanistic map is compelling for how the system works. It is less clear how to convert that map into safe, effective interventions for people.